A study to assess the efficacy of preoperative IV Tranexenamic acid in reducing intraoperative blood loss in cancer patients
Not Applicable
- Conditions
- Health Condition 1: C50- Malignant neoplasm of breastHealth Condition 2: C15-C26- Malignant neoplasms of digestive organsHealth Condition 3: C51-C58- Malignant neoplasms of female genital organsHealth Condition 4: C00-C14- Malignant neoplasms of lip, oral cavity and pharynxHealth Condition 5: C45-C49- Malignant neoplasms of mesothelial and soft tissueHealth Condition 6: O- Medical and SurgicalHealth Condition 7: C00-D49- Neoplasms
- Registration Number
- CTRI/2023/03/050390
- Lead Sponsor
- nil
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- ot Yet Recruiting
- Sex
- Not specified
- Target Recruitment
- 0
Inclusion Criteria
all cancer patients undergoing surgeries for breast gyanecology, Head &neck ,GI, soft tissue sarcoma& others
Exclusion Criteria
Patients with coagulopathy(activated partial thromboplastin time >50 s or International normalised ratio >1.5, platelets <50 X 109/L), Recent history of acetylsalicylic acid ingestion ( < 5 days), Patients on anticoagulation therapy (received heparin within 4 hours or received warfarin 3 days preoperatively), Those with known peripheral vascular disease, Pre-existing renal dysfunction (serum creatinine >1.2 mg/dl), Liver dysfunction, Known allergy to tranexamic acid
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method 1. Operative blood loss <br/ ><br>2. Blood transfusion rates <br/ ><br>Timepoint: baseline <br/ ><br>
- Secondary Outcome Measures
Name Time Method 1.Length of hospital stay <br/ ><br>2.Length of stay in ICU <br/ ><br>3.DVT <br/ ><br>4.Pulmonary embolism <br/ ><br>Timepoint: 5 days